The latest price target for Gritstone Bio (NASDAQ:GRTS) was reported by HC Wainwright & Co. on August 15, 2024. The analyst firm set a price target for $4.00 expecting GRTS to rise to within 12 months (a possible 545.68% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Gritstone Bio (NASDAQ:GRTS) was provided by HC Wainwright & Co., and Gritstone Bio reiterated their buy rating.

There is no last upgrade for Gritstone Bio

The last downgrade for Gritstone Bio Inc happened on August 22, 2022 when Goldman Sachs changed their price target from N/A to $2 for Gritstone Bio Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gritstone Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gritstone Bio was filed on August 15, 2024 so you should expect the next rating to be made available sometime around August 15, 2025.

While ratings are subjective and will change, the latest Gritstone Bio (GRTS) rating was a reiterated with a price target of $4.00 to $4.00. The current price Gritstone Bio (GRTS) is trading at is $0.62, which is out of the analyst’s predicted range.